IP Library › Granted Patent US 11,382,897
Granted Patent B2
US 11,382,897 · App. 16/182,965 · Granted Jul 12, 2022

Therapeutic combination for treatment of cerebellar ataxia

Inventors: Vikram Shakkottai (Ann Arbor, MI); David Bushart (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan
A61K31/423A61K31/197A61P21/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,382,897
App. No.
16/182,965
Granted
Jul 12, 2022
Kind
B2
Abstract

Provided herein are combinations of therapeutic agents useful for the treatment of cerebellar ataxia and methods of use thereof. In particular, embodiments herein baclofen and chlorzoxazone are administered for the treatment of cerebellar ataxia.

Claims (15)

1. A method of treating a subject suffering from cerebellar ataxia, comprising:

co-administering to a subject an effective amount of baclofen and chlorzoxazone, such that the cerebellar ataxia or symptoms thereof are reduced.

2. The method of claim 1 , wherein the subject is human.

3. The method of claim 1 , wherein the baclofen and chlorzoxazone are co-formulated in a single pharmaceutical composition.

4. The method of claim 1 , wherein the baclofen and chlorzoxazone are separately-formulated in a single pharmaceutical composition.

5. The method of claim 1 , wherein the baclofen and chlorzoxazone are in separate pharmaceutical compositions.

6. The method of claim 5 , wherein the separate pharmaceutical compositions are co-administered sequentially.

7. The method of claim 6 , wherein administrations are separated by a delay of at least 1 hour.

8. The method of claim 6 , wherein administrations are separated by a delay of at least 1 day.

9. The method of claim 1 , further comprising a step comprising testing the subject cerebellar ataxia.

10. The method of claim 9 , further comprising the step of assessing the effectiveness of treatment based upon said testing.

11. The method of claim 10 , further comprising adjusting the treatment based on said assessing.

12. The method of claim 11 , wherein adjusting the treatment comprises one or more of: altering the dose of baclofen, altering the dose of chlorzoxazone, altering the dosing regimen of baclofen, altering the dosing regimen of chlorzoxazone, or adding additional treatment.

13. The method of claim 1 , wherein the baclofen and chlorzoxazone are co-formulated in a single pharmaceutical composition.

14. The method of claim 1 , wherein the baclofen and chlorzoxazone are separately-formulated in a single pharmaceutical composition.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 20, 2021
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 057529/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2018
From: SHAKKOTTAI, VIKRAM; BUSHART, DAVID
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 047647/0788 →
Continuity (2)
Provisional Application 62582405 · Nov 7, 2017
Related Publication 20190134007A1 · May 9, 2019